- Dr. Adam M. Brufsky of University of Pittsburgh School of Medicine and Dr. Saranya Chumsri of Mayo Clinic will discuss the current treatment landscape for patients with advanced metastatic breast cancer and the latest clinical data of the Bria-IMT™ regimen
- BriaCell recently reported benchmark-beating patient survival and clinical benefit with median overall survival of 13.5 months in BriaCell's advanced metastatic breast cancer patients (vs. 6.7-9.8 months for similar patients reported in the literature)
- Bria-IMT™ has been awarded Fast Track status by the U.S Food and Drug Administration for the treatment of advanced metastatic breast cancer and initiated a phase 3 pivotal registration study.
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 11, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces that it will host a virtual KOL event on Bria-IMT™ potential in advanced metastatic breast cancer on Thursday, October 26, 2023 at 10:00am ET. To register for the event, please click here.
The event will feature KOLs Adam M. Brufsky, MD, PhD, FACP (University of Pittsburgh School of Medicine) and Saranya Chumsri, MD (Mayo Clinic) who will discuss the unmet medical need and current treatment landscape for patients suffering from advanced metastatic breast cancer, along with the combination study of Bria-IMT™ with immune check point inhibitor.
Dr. William V. Williams, BriaCell's President & CEO, and Dr. Giuseppe Del Priore, BriaCell's Chief Medical Officer, will provide a pipeline overview and highlight the next steps for the Phase 3 study, and will be available to answer questions.
The event's agenda is summarized below:
BriaCell Virtual KOL Event Agenda – October 26, 2023
Dr. William Williams (CEO) – Introduction and opening remarks
Dr. Giuseppe Del Priore (CMO) – Event agenda and KOL introductions
Dr. Adam Brufsky (KOL) – Review all metastatic breast cancer and current treatment landscape
Dr. Saranya Chumsri (KOL) – Bria-IMT™ Clinical data to date & Phase 3 clinical study details
Q&A
Drs. Del Priore and Williams – Summary and next steps
About Adam M. Brufsky, ...